Achieve Life Sciences, Inc.
General ticker "ACHV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $242.9M (TTM average)
Achieve Life Sciences, Inc. follows the US Stock Market performance with the rate: 55.7%.
Estimated limits based on current volatility of 3.4%: low 6.67$, high 7.13$
Factors to consider:
- Total employees count: 28 (+12.0%) as of 2025
- Top business risk factors: Economic downturns and volatility, Capital raising failure, Regulatory and compliance, Clinical trial delays, Single product reliance
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.85$, 7.59$]
- 2026-12-31 to 2027-12-31 estimated range: [2.37$, 6.48$]
Financial Metrics affecting the ACHV estimates:
- Positive: with PPE of -3.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 49.86 < Shareholder equity ratio, % of 51.49 <= 58.56
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term ACHV quotes
Long-term ACHV plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $27.25MM | $39.07MM | $54.88MM |
| Operating Income | $-27.25MM | $-39.07MM | $-54.88MM |
| Non-Operating Income | $-2.56MM | $-0.76MM | $0.23MM |
| Interest Expense | $2.85MM | $2.18MM | $0.82MM |
| R&D Expense | $15.81MM | $22.82MM | $22.96MM |
| Income(Loss) | $-29.82MM | $-39.83MM | $-54.65MM |
| Net Income(Loss)* | $-29.82MM | $-39.83MM | $-54.65MM |
| Stockholders Equity | $-1.45MM | $20.90MM | $21.52MM |
| Assets | $19.37MM | $38.63MM | $41.79MM |
| Operating Cash Flow | $-24.48MM | $-29.77MM | $-49.47MM |
| Capital expenditure | $0.02MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.02MM | $-21.58MM | $6.11MM |
| Financing Cash Flow | $15.28MM | $48.53MM | $51.53MM |
| Earnings Per Share** | $-1.50 | $-1.24 | $-1.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.